ArticlePloS one2023

Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.

Virginie Westeel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.